Palvella Therapeutics Inc expected to post a loss of $1.21 a share - Earnings Preview

Palvella Therapeutics

13/05/2025 15:45

Palvella Therapeutics Inc PVLA.OQ PVLA.O is expected to report resultson May 15 for the period ending March 31 2025

​LSEG's mean analyst estimate for Palvella Therapeutics Inc is for a loss of $1.21 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 65.4% in the last three months. ​

Wall Street's median 12-month price target for Palvella Therapeutics Inc is $49.00​, above​ its last closing price of $20.75. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.66
-0.64
-2.72
Missed
-321.7
2024
​
​​
-3.70
Sep. 30 2023
-8.80
-8.80
3.20
Beat
136.4​
Jun. 30 2023
-12.80
-12.80
4.00
Beat
131.3
Mar. 31 2023
-10.73
-11.20
-14.40
Missed
-28.6

This summary was machine generated May 13 at 14:45 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)